4523 JP3160400002

Report

End-of-day quote Japan Exchange - 04/21
7216	JPY		-1.76%

02:01a

BIOARCTIC : Interim Report for the period January - March 2021

04/20

BIOARCTIC : Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

04/19

EISAI : 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Japan Exchange

04/15/2021	04/16/2021	04/19/2021	04/20/2021	04/21/2021	Date
7196	7243	7339	7345	7216	Last
548400	491200	643700	738400	854000	Volume
-0.06%	+0.65%	+1.33%	+0.08%	-1.76%	Change

Financials

Sales 2021	659 B 6 094 M 6 094 M
Net income 2021	46 073 M 426 M 426 M
Net cash position 2021	163 B 1 504 M 1 504 M
P/E ratio 2021	44,7x
Yield 2021	2,18%

Sales 2022	707 B 6 532 M 6 532 M
Net income 2022	66 513 M 615 M 615 M
Net cash position 2022	178 B 1 642 M 1 642 M
P/E ratio 2022	32,0x
Yield 2022	2,25%

Capitalization	2 106 B 19 473 M 19 461 M
EV / Sales 2021	2,95x
EV / Sales 2022	2,73x
Nbr of Employees	10 998
Free-Float	87,5%

More Financials

Company

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

04/20 | 05:00am

Presentation

More about the company

Notations Surperformance© of Eisai Co., Ltd.

Trading Rating :

Investor Rating :

More Ratings

All news about EISAI CO., LTD.

02:01a	BIOARCTIC : Interim Report for the period January - March 2021	AQ
04/20	BIOARCTIC : Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease pub..	AQ
04/19	EISAI : 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinica..	AQ
04/14	EISAI : to Present Latest Data on Neurology Products and Pipelines at the Ameri..	AQ
04/12	EISAI : Animation Featuring Lymphatic Filariasis Elimination Activities Receives..	AQ
04/01	EISAI : And advocacy leaders team up to launch spot her - an initiative that em..	AQ
04/01	EISAI : Application submitted for additional indication of anti cancer agent le..	AQ
03/31	EISAI : KYORIN and Eisai Enter Into License Agreement Concerning the Developmen..	AQ
03/31	EISAI : Application Submitted for Additional Indication of Anti Cancer Agent Len..	AQ
03/30	EISAI : European medicines agency accepts the marketing authorisation applicati..	AQ
03/30	EISAI : European Medicines Agency Accepts the Marketing Authorisation Applicatio..	AQ
03/30	EISAI CO., LTD. : Ex-dividend day for final dividend	FA
03/26	EISAI : Discovery research on ampa-type glutamate receptor antagonist perampane..	AQ
03/25	EISAI : Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel..	AQ
03/24	EISAI : ANTICANCER AGENT Remitoro INTRAVENOUS DRIP INFUSION 300g APPROVED IN JA..	AQ

More news

News in other languages on EISAI CO., LTD.

01/12	TOKYO STOCK EXCHANGE : Borsa Tokyo, nuovo massimo da 30 anni, farmaceutici in ra..
01/11	EISAI : Medicamento de Eli Lilly para el alzhéimer retrasa declive mental y fun..
2020	TOKYO STOCK EXCHANGE : Borsa Tokyo chiude a massimo 29 anni su rimbalzo Pil, pro..
2020	Les Bourses mondiales savourent la victoire de Biden
2020	TOKYO STOCK EXCHANGE : Borsa Tokyo chiude a massimi di circa 30 anni su Biden vi..

More news

Analyst Recommendations on EISAI CO., LTD.

2020	Nikkei hits over 2-year high on Wall Street boost, focus on final U.S. electi..	RE
2020	Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, share..	RE
2019	Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value	RE

More recommendations

Stock Trading Strategies

	EISAI CO., LTD. - 2020
The calm spell can be taken advantage of to put on new positions

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

U.S. FDA extends review period for Biogen's Alzheimer's drug to June